| Product Code: ETC9966865 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 | |
The United States continued to rely on a diverse set of countries for its generic injectables import shipments in 2024, with top exporters including Switzerland, Ireland, India, Italy, and Singapore. Despite the low concentration indicated by the Herfindahl-Hirschman Index (HHI), the market saw a significant decline in both the compound annual growth rate (CAGR) and the growth rate from 2023 to 2024. This may reflect various factors impacting the import market, such as regulatory changes, market competition, or shifts in demand dynamics.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Generic Injectables Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Generic Injectables Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Generic Injectables Market - Industry Life Cycle |
3.4 United States (US) Generic Injectables Market - Porter's Five Forces |
3.5 United States (US) Generic Injectables Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.6 United States (US) Generic Injectables Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.7 United States (US) Generic Injectables Market Revenues & Volume Share, By Container Type, 2021 & 2031F |
3.8 United States (US) Generic Injectables Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
4 United States (US) Generic Injectables Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing demand for cost-effective generic drugs |
4.2.2 Rising prevalence of chronic diseases requiring injectable treatments |
4.2.3 Patent expirations leading to opportunities for generic injectables manufacturers |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for approval of generic injectables |
4.3.2 Limited reimbursement policies impacting pricing and profitability |
4.3.3 Intense competition among generic injectables manufacturers |
5 United States (US) Generic Injectables Market Trends |
6 United States (US) Generic Injectables Market, By Types |
6.1 United States (US) Generic Injectables Market, By Product Type |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Generic Injectables Market Revenues & Volume, By Product Type, 2021- 2031F |
6.1.3 United States (US) Generic Injectables Market Revenues & Volume, By Large Molecule Injectables, 2021- 2031F |
6.1.4 United States (US) Generic Injectables Market Revenues & Volume, By Small Molecule Injectables, 2021- 2031F |
6.2 United States (US) Generic Injectables Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Generic Injectables Market Revenues & Volume, By Oncology, 2021- 2031F |
6.2.3 United States (US) Generic Injectables Market Revenues & Volume, By Infectious Diseases, 2021- 2031F |
6.2.4 United States (US) Generic Injectables Market Revenues & Volume, By Cardiology, 2021- 2031F |
6.2.5 United States (US) Generic Injectables Market Revenues & Volume, By Diabetes, 2021- 2031F |
6.2.6 United States (US) Generic Injectables Market Revenues & Volume, By Immunology, 2021- 2031F |
6.2.7 United States (US) Generic Injectables Market Revenues & Volume, By Others, 2021- 2031F |
6.3 United States (US) Generic Injectables Market, By Container Type |
6.3.1 Overview and Analysis |
6.3.2 United States (US) Generic Injectables Market Revenues & Volume, By Vials, 2021- 2031F |
6.3.3 United States (US) Generic Injectables Market Revenues & Volume, By Premix, 2021- 2031F |
6.3.4 United States (US) Generic Injectables Market Revenues & Volume, By Prefilled Syringes, 2021- 2031F |
6.3.5 United States (US) Generic Injectables Market Revenues & Volume, By Ampoules, 2021- 2031F |
6.3.6 United States (US) Generic Injectables Market Revenues & Volume, By Others, 2021- 2031F |
6.4 United States (US) Generic Injectables Market, By Route of Administration |
6.4.1 Overview and Analysis |
6.4.2 United States (US) Generic Injectables Market Revenues & Volume, By Intravenous, 2021- 2031F |
6.4.3 United States (US) Generic Injectables Market Revenues & Volume, By Intramuscular, 2021- 2031F |
6.4.4 United States (US) Generic Injectables Market Revenues & Volume, By Subcutaneous, 2021- 2031F |
6.4.5 United States (US) Generic Injectables Market Revenues & Volume, By Others, 2021- 2031F |
7 United States (US) Generic Injectables Market Import-Export Trade Statistics |
7.1 United States (US) Generic Injectables Market Export to Major Countries |
7.2 United States (US) Generic Injectables Market Imports from Major Countries |
8 United States (US) Generic Injectables Market Key Performance Indicators |
8.1 Average selling price of generic injectables |
8.2 Number of FDA approvals for generic injectables |
8.3 Market penetration rate of generic injectables compared to branded counterparts |
9 United States (US) Generic Injectables Market - Opportunity Assessment |
9.1 United States (US) Generic Injectables Market Opportunity Assessment, By Product Type, 2021 & 2031F |
9.2 United States (US) Generic Injectables Market Opportunity Assessment, By Application, 2021 & 2031F |
9.3 United States (US) Generic Injectables Market Opportunity Assessment, By Container Type, 2021 & 2031F |
9.4 United States (US) Generic Injectables Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
10 United States (US) Generic Injectables Market - Competitive Landscape |
10.1 United States (US) Generic Injectables Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Generic Injectables Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |